*Recently, OPM provided an H1 update, most notably confirming Ph1b/2a commencement with OPM-101 end of 2024/early 2025. *Furthermore, the company indicated that the Ph1 for Parkinson's disease with OPM-201 is wrapping up soon - we expect results in H1 2025 (10% TP upside) – with Servier preparing for a follow-up Ph1b/2a study which is likely to trigger a milestone payment and consequently strengthen OPM's cash position (which stood at close to EUR 10m end of June).*Based on an updated net cash p ....
